Introduction
Small intestinal bacterial overgrowth (SIBO) is defined as 10 5 CFU/ml or more bacterial cells present in the proximal small bowel [1] . SIBO increases intestinal permeability, which acts as a template for bacterial peritonitis and chronic inflammation in cirrhotic patients, and can lead to bacterial translocation [1] [2] [3] [4] [5] [6] [7] [8] [9] . The increased intestinal permeability associated with SIBO is considered to increase the influx of lipopolysaccharide (LPS) endotoxin to the liver, aggravate chronic liver diseases, exacerbate digestive symptoms, and ultimately lead to complications [1] [2] [3] [4] [5] . Increased intestinal motility and altered stomach acidity or bile acid composition are considered to be related to SIBO [10] [11] [12] [13] . Various treatments such as probiotics, prokinetics, and antibiotics are used to treat SIBO [5, 14, 15] . The effects of probiotics on portal pressure and cirrhotic complications have been studied recently.
Even though many animal studies indicate that probiotic therapy has beneficial effects on various liver diseases, the evidence for beneficial effects in the clinical field is very limited. There are reports that administration of probiotics decreased systemic inflammation and portal pressure in cirrhosis [2, 3, 5, 16] . However, Pereg et al. [4] found that probiotic administration to patients with decompensated cirrhosis for 6 months did not result in significant improvement in liver function. Loguercio et al. [3] reported that the administration of a composite probiotic in patients with various chronic liver diseases decreased malondialdehyde and 4-hydroxynonenal, but failed to alter the levels of tumor necrosis factor-α, interleukin-6, and interleukin-10. Lata and colleagues found that administration of Escherichia coli strain Nissle led to the restoration of colonic flora and improvement in Child-Pugh scores [2] . Despite the promising results in experimental models and limited clinical evidence in chronic liver disease, welldesigned placebo-controlled studies are clearly needed.
Most previous clinical trials have focused on the improvement of clinical parameters, for example, liver chemistry, the serum cytokine level, hepatic vein wedge pressure gradient, etc. Although reversal of SIBO and intestinal permeability are considered to underlie the clinical improvements after probiotic administration, there are no clinical studies indicating that probiotics administered to patients with chronic liver disease alter SIBO and intestinal permeability. In addition, there are several unanswered questions such as the optimal treatment duration, safety, the best combinations of probiotic species, etc.
The aim of this study was to examine the effects of probiotic administration on SIBO and intestinal permeability in patients with chronic liver disease.
Methods Patients
A total of 53 chronic liver disease patients (alcoholic liver disease, chronic hepatitis B, chronic hepatitis C) ranging in age from 18 to 65 years participated in this study. The participants had undergone colonoscopy in the last 5 years and had been confirmed to have no organic abnormality of their large intestine. The exclusion criteria were as follows: (a) sensitivity to probiotics, (b) weekly alcohol consumption of 21 drinks or more for men and 14 drinks or more for women, (c) diagnosis of congestive heart failure, angina, (d) lactulose intolerance, (e) immunosuppressed status, and (f) decreased renal function (creatinine > 2.0 mg/dl). The patients were all asked to report any medication currently taken, including antibiotics, NSAIDs, and prokinetics, to rule out the influence of medication on the study outcomes.
Study design and procedures
The patients fulfilling the study requirement were assigned randomly to probiotic and placebo groups of equal size when they registered. The randomization was computer generated in a sequence based on a block size of five with allocations hidden in a sealed envelope. The probiotic group received Duolac Gold probiotic (Cell Biotech Co., Ltd, Gimpo, Korea) containing six strains of lactic acid bacteria: Bifidobacterium bifidum (KCTC 12199BP), Bifidobacterium lactis (KCTC 11904BP), Bifidobacterium longum (KCTC 12200BP), Lactobacillus acidophilus (KCTC 11906BP), Lactobacillus rhamnosus (KCTC 12202BP), and Streptococcus thermophilus (KCTC 11870BP). Each capsule contained 5 × 10 9 viable cells in lyophilized powder form, and the placebo was also in capsule form and identical in appearance. The practice nurse, who was blinded to the treatments, investigated patients' medical history, clinical symptoms, and current medication by questionnaire, and explained the protocol to the patients. Baseline parameters were noted and tests were performed to evaluate liver chemistry, intestinal permeability, and SIBO. Probiotics and placebo were administered twice daily for 4 weeks after fecal specimens were collected in week 0 for bacterial quantification. At the end of 4 weeks, the patients were re-evaluated. Compliance was checked by the practice nurse, and patients with compliance below 70% were planned to be eliminated from the study. Every patient in fact took at least 90% of the medication.
Assessment of intestinal permeability
Intestinal permeability was assessed by highperformance liquid chromatography using the lactulose/ mannitol ratio in urine. Patients fasted for 8 h, ingested 5 g lactulose and 1 g mannitol dissolved in 100 ml water, and took 50-150 ml of water 2 h after test initiation. Four hours later, the amount of urine was measured and a 10 ml aliquot was frozen at − 20°C and after thawing, fractionated on an ODS column. Samples were analyzed using a refractory index detector, and the fractional excretion was calculated as the ratio of excretion to intake. The lactulose/mannitol ratio was calculated using the fractional excretion ratios for mannitol and lactulose, and the lactulose/mannitol ratio expressed as a percentage was used as an index of intestinal permeability. Permeability was considered to be increased when the ratio was 6 or more [17] .
Measurement of small intestinal bacterial overgrowth
SIBO was measured using the hydrogen breath test. Twenty-four hour-fasted patients took 10 g lactulose with 250 ml water in 2 min and were tested for exhaled hydrogen at 15 min intervals for 90 min. Expiratory gas was collected using a customized collector to evaluate the hydrogen content of the expirate. The expirate was analyzed using an automatic analyzer (Quintron, Milwaukee, Wisconsin, USA). Patients were labeled positive when the baseline content of hydrogen gas reached 20 ppm or more, or increased above 20 ppm within 90 min [18] .
Assessment of clinical symptoms
Clinical symptoms (stomach ache, abdominal discomfort, diarrhea, constipation, bloating, and excessive flatulence) were assessed on a scale from 1 to 5 (1 for no discomfort, 2 for slight, 3 for moderate, 4 for severe, and 5 for extremely severe discomfort). Patients were also asked to report the frequency of fecal excretion and stomach ache on a weekly basis. The averages of each clinical symptom 1 week before and 4 weeks after drug administration were compared. At the visit in the fourth week, the extents of improvement in discomfort, abdominal pain, bowel habit, and quality of life were also assessed (0 for no improvement to 10 for great improvement).
Quantification of fecal bacteria
Fecal samples collected at the beginning and end of the study in sterile containers were brought to the laboratory frozen and stored at − 80°C until analyzed. Clonal bacterial cultures for counting and genomic DNA extraction were cultivated at 37°C for 13-18 h under anaerobic conditions. An AccuPrep Genomic DNA extraction kit (Bioneer, Daejeon, Korea) was used to extract DNA from 1 ml of culture or fecal samples according to the manufacturer's instructions. Quantitative PCR was performed using 96-well plates in final volumes of 20 μl [containing 1 μl of fecal DNA, 0.5 μl of primers (10 pmol each), 10 μl SYBR Green I master (Roche, Mannheim Germany), and 8 μl of Light Cycler 480 in H 2 O (Roche)]. PCR amplification was carried out as follows: preincubation at 94°C for 4 min and 55 cycles of amplification (denaturation at 94°C for 15 s, primer annealing at 55°C for 15 s, and elongation at 72°C for 20 s). Primers were synthesized commercially by Bioneer and their specificities were verified using DNAs from closely or distantly related bacteria as templates. Group-specific and species-specific PCR primers are listed in Table 1 . Standard curves for bacterial quantification were constructed using DNAs of Staphylococcus epidermis (KCTC 1917) for Gram-positive bacteria and E. coli (KCCM 40406) for Gram-negative bacteria. DNA concentrations were determined using an e-spect (Malcom, Tokyo, Japan). Total cell numbers were determined using a hemocytometer (Marienfeld Superior, Marienfeld, Germany). The cross point values of each dilution were plotted against the total cell number. Total cell numbers of each species in 1 g feces were calculated from the standard curves.
Study outcomes
The primary outcome was the decrease in SIBO after 4 weeks of treatment relative to the baseline value. 
Ethical statement
The study was approved by the institutional review board of Hanyang University School of Medicine (HYUH IRB 2010-C-62) and each participant signed a written consent. This study was registered at the CRIS (Clinical research information service. http://cris.nih.go.kr/cris/index. jsp) with registration number KCT0000081.
Sample size
The sample size for this study was calculated assuming a 20% difference in the primary endpoint between the two groups. From this assumption, we calculated that a total of 50 patients would have a statistical power of 80% and a two-sided α risk of 0.05. We enrolled 53 patients as we expected some participants to drop out of the study.
Statistical analysis
SPSS for Windows version 18.0 (SPSS Inc., Chicago, Illinois, USA) was used for statistical analysis. Student's t-test was performed for continuous variables and the χ 2 -test for discrete variables. Paired t-tests were carried out to examine the test results and clinical symptoms before and after drug administration. The test results are shown as mean SD and differences were considered to be statistically significant at P-value less than 0.05.
Results

Patients
A total of 53 patients were enrolled in the study; 52 (98.1%) were randomized to either probiotic or placebo for 4 weeks and evaluated by a per-protocol analysis. Of these 52 patients, one, in the probiotic group, withdrew from participation and one in the placebo group was eliminated because of protocol violation. Finally, 50 patients, 25 in the probiotics group and 25 in the placebo group, completed the study (Fig. 1 ). Baseline characteristics of the patients, age, sex, etiology of liver disease, and liver chemistry were similar in the two groups ( Table 2) . 
Changes in small intestinal bacterial overgrowth
The prevalence of SIBO was 26% in the chronic liver disease patients (Table 3) . SIBO-positive rates were 50, 29, and 21% in the chronic hepatitis C, alcoholic liver disease, and chronic hepatitis B patients, respectively (P = 0.47).
The SIBO improved in 24% of the patients after 4 weeks' treatment in the probiotic group, but in the placebo group, none of the patients improved, and in 16% of these patients, the SIBO worsened (P < 0.05) (Fig. 2) .
Analysis of fecal bacteria
The changes in fecal bacterial composition in the two groups were examined at the end of treatment. In the probiotic group, there was an increase in the level of fecal B. lactis, L. rhamnosus, and L. acidophilus (P < 0.05). Although the probiotic contained B. bifidum, B. longum, and S. thermophilus, the changes in the levels of B. bifidum, B. longum, and S. thermophilus were not significant, although there was a strong tendency for the level of B. bifidum to increase (P = 0.08) ( Table 4 ). By contrast, there were no significant changes in the levels of the ingested bacteria in the placebo group. When the total numbers of bifidobacteria and lactobacilli were quantified, the bifidobacterial level showed a tendency to increase in the probiotic group (P = 0.063), whereas there was no significant change in the level of lactobacilli. Meanwhile, the numbers of both bacterial groups in the placebo patients remained unchanged. There were no significant changes in the ratio of Gram-positive to Gramnegative bacteria in either group of patients.
Changes in intestinal permeability
Intestinal permeability improved in about 50% of the patients in the probiotic group and 31.3% of the patients in the placebo group, but the difference was not statistically significant (P = 0.248) ( Fig. 3) . When the patients were divided into tertiles according to the number of lactobacilli in the fecal specimens taken before treatment, intestinal permeability was highest in the lowest tertile and there was an inverse correlation between the number of lactobacilli in stool and intestinal permeability (P = 0.029) ( Fig. 4 ). However, there was no significant correlation between numbers of bifidobacilli and intestinal permeability (P = 0.297). In the relation between intestinal permeability and complication of cirrhosis (ascites), degree of intestinal permeability was not different according to ascites status (P = 0.428).
Changes in liver chemistry and clinical symptoms
The improvements in abdominal pain in the probiotics and placebo groups were 3.17 1.60 and 1.95 2.40, respectively (P = 0.056) (Table 5) . Similarly, the improvements in gastrointestinal symptoms of the probiotic and placebo group were 3.35 1.70 and 2.05 2.30, respectively, suggesting that the digestive symptoms of the probiotic group improved compared with the placebo (P = 0.047). The improvements in bowel habits of the probiotic and placebo group were 3.35 1.84 and 2.50 2.64, respectively (P = 0.226), and those in quality of life were 3.39 1.77 and 2.47 2.68, respectively (P = 0.177). Biochemical parameters and Child-Pugh scores were unchanged in both groups (Table 6 ). 
Correlation between SIBO and intestinal permeability
SIBO-positive patients had higher intestinal permeability indices than SIBO-negative patients (14.22 21.8 vs. 4.08 6.9, P = 0.089). In the SIBO-improved and SIBOunimproved groups intestinal permeability indices decreased from 25.12 34.7 to 11.30 12.8 and from 5.81 7.7 to 3.73 6.9, respectively. However, these differences were not statistically significant (P = 0.503).
Discussion
Probiotic administration for 4 weeks in chronic liver disease patients resulted in alleviation of SIBO and digestive symptoms, but was ineffective in improving liver chemistry and Child-Pugh scores. SIBO increases the intestinal permeability of patients with chronic liver disease and the inflow of LPS to the portal vein, causing bacterial translocation to regional lymph nodes and ascites. Bacterial translocation plays an important role in triggering cirrhotic complications such as hepatic encephalopathy, spontaneous bacterial peritonitis, and hepatorenal syndrome [3, 5, 8, [18] [19] [20] . Previous studies have suggested that the use of probiotics can help reduce the occurrence of minimal hepatic encephalopathy and spontaneous bacterial peritonititis and improve liver function. However, none of those studies examined the effects of probiotics on SIBO and intestinal permeability. Changes in the fecal bacteria flora were reported after In the present study, we evaluated fecal bacteria composition and also SIBO and intestinal permeability. Moreover, because short-term probiotics therapy was known to be associated with reducing endotoxemia and improving liver function [21] , we planned to investigate the effect of 4 weeks of probiotics therapy on SIBO and intestinal permeability. After four weeks' treatment, SIBO had improved in 24% of the patients in the probiotic group and in 5%, the SIBO had worsened, but SIBO failed to improve in any of the placebo patients and it worsened in 16% (P < 0.05). The improvement of SIBO is believed to be caused by successful colonization of the small intestine by the probiotics; however, it did not lead to an improvement in intestinal permeability. Structural and functional changes in the intestinal mucosa are assumed to contribute toward the increased intestinal permeability, and portal hypertension is considered to be an important determinant of these structural abnormalities [5] ; the duration of probiotic treatment may not have been long enough to alleviate portal hypertension or more time may be needed for the improvement in intestinal permeability to result in normalization of the structural abnormalities. However, it was interesting to find that following probiotic administration, the reduction in SIBO was because of a decrease in hydrogen-producing bacteria, whereas there was no significant reduction in methane-producing bacteria in either patient group. Our results are similar to those of Sabaté et al. [22] , who compared SIBO in nonalcoholic steatohepatitis and healthy individuals.
Previous studies suggested that probiotic treatment improved liver function; however, no such effects on alanine aminotransferase, bilirubin, or Child-Pugh score were found in our study. The difference between our results and those of Lata et al. [2] and Loguercio et al. [3] may be because of the fact that in those studies, 70% of patients were Child-Pugh class B or C and probiotics were administered for 6 weeks and 3 months, respectively. In our study, Child-Pugh class B or C patients accounted for only 14% of the total patients and probiotics were administered only for 4 weeks. Although we used a multispecies probiotic mixture, only three strains (B. lactis, L. rhamnosus, L. acidophilus) had increased at 4 weeks (P = 0.001), and among these, the numbers of lactobacilli were correlated negatively with intestinal permeability (Fig. 4) . Moreover, the top one-third of the patients in terms of numbers of lactobacilli had the least symptoms of stomach discomfort, diarrhea, and excessive gas. These results suggest that probiotic administration leads not only to an increase in the number of lactobacilli but also to an improvement in clinical symptoms of stomach discomfort, diarrhea, and excessive gas. This supports the idea that probiotic administration in chronic liver disease patients can be helpful in alleviating intestinal permeability and digestive symptoms.
This study has some limitations. First, jejunal aspiration is the gold standard for the diagnosis of SIBO. However, it is an invasive method and detects less than 40% of small intestinal bacteria [23] and we instead used the hydrogen breath test to assess SIBO as it is noninvasive and can be repeated easily. But defective absorption of carbohydrate, oral bacteria, and a high-fiber diet may produce false-positive results, and antibiotic treatment as well as an insufficient number of hydrogen gas-producing bacteria may result in false negatives [24] .
Second, most of the patients enrolled had relatively compensated liver function (Child A) and did not show significant changes in intestinal permeability and liver chemistry after probiotic administration. The reason for this was related to safety: administration of probiotics in immunocompromised patients, such as decompensated liver cirrhosis, was not guaranteed. Further study with decompensated cirrhotic patients may be needed. Finally, LPS is an important surrogate marker of leaky gut syndrome, but was not tested in our study.
In summary, 4 weeks of probiotic treatment restored SIBO and improved digestive symptoms. However, it did not significantly improve intestinal permeability and liver function. Therefore, a long-term treatment study is needed to assess the effects of probiotics on intestinal permeability and liver chemistry. 
